DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents

Current Topics in Medicinal Chemistry

Volumn 5, Issue 12, 2005, Pages 1133-1149

  Pors, Klaus ^a   Patterson, Laurence H ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ANTHRAQUINONE DERIVATIVE; ANTIMETABOLITE; BUSULFAN; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LOMUSTINE; MERCAPTOPURINE; METHYLNITROSOUREA; MITOMYCIN C; OXALIPLATIN; PLATINUM DERIVATIVE; PROCARBAZINE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MUTS; PURINE NUCLEOTIDE; TEMOZOLOMIDE; TIOGUANINE; TOPOTECAN; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CANCER RISK; COLON CARCINOMA; COLORECTAL CANCER; DNA DAMAGE; DNA REPLICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; FEASIBILITY STUDY; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MISMATCH REPAIR; PHENOTYPE; PROMOTER REGION; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REVIEW; STRUCTURE ANALYSIS; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BASE PAIR MISMATCH; DNA; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 27844605955     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802605774370883     Document Type: Review

References (136)

1. Gatti, L, Zunino, F. Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. 2005, 111, 127-48.
2. Freireich, E.J. Treatment of malignancies, past and present. Hosp. Pract. 1993, 28, 109-113, 116, 122-126.
3. Frankel, A.; Man, S.; Elliott, P.; Adams, J.; Kerbel, R.S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 2000, 6, 3719-28.
4. Lehnert, M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur. J. Cancer 1996, 32A, 912-20.
5. Baird, R.D.; Kaye, S.B. Drug resistance reversal - are we getting closer? Eur. J. Cancer 2003, 39, 2450-61.
6. Leslie, E.M.; Deeley, R.G.; Cole, S.P.; Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204, 216-37.
7. Leonard, G.D.; Fojo, T.; Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8, 411-24.
8. Morimoto, H.; Tsukada, J.; Kominato, Y.; Tanaka, Y. Reduced expression of human mismatch repair genes in adult T-cell leukemia. Am. J. Hematol. 2005, 78, 100-7.
9. Chai, S.M.; Zeps, N.; Shearwood, A.M.; Gricu, F.; Charles, A.; Harvey, J.; Goldblatt, J.; Joseph, D.; Iacopetta, B. Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. Clin. Gastroenterol. Hepatol. 2004, 2, 1017-25.
10. Kitajima, Y.; Miyazaki, K.; Matsukura, S.; Tanaka, M.; Sekiguchi, M. Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer. Gastric Cancer 2003, 6, 86-95.
11. Zekri, A.R.; Sabry, G.M.; Bahnassy, A.A.; Shalaby, K.A.; Abdel-Wahabh, S.A.; Zakaria, S. Mismatch repair genes (hMLH1, hPMS1, hPMS2, GTBP/hMSH6, hMSH2) in the pathogenesis of hepatocellular carcinoma. World J Gastroenterol. 2005, 11, 3020-6.
12. Murata, H.; Khattar, N.H.; Gu, L.; Li, G.M. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett. 2005, 223, 143-50.
13. Chen, Y.; Wang, J.; Fraig, M.M.; Henderson, K.; Bissada, N.K.; Watson, D.K.; Schweinfest, CW. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int. J. Oncol. 2003, 22, 1033-43.
14. Gifford, G.; Paul, J.; Vasey, P.A.; Kaye, S.B.; Brown, R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 2004, 10, 4420-6.
15. Irving, J.A.; Hall, A.G. Mismatch repair defects as a cause of resistance to cytotoxic drugs. Expert Rev. Anticancer Ther. 2001, 1, 149-58.
16. Kolodner, R.D. Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem. Sci. 1995, 20, 397-401.
17. Lamers, M.H.; Perrakis, A.; Enzlin, J.H.; Winterwerp, H.H.; de Wind, N.; Sixma, T.K. The crystal structure of DNA mismatch repair protein MutS binding to a G × T mismatch. Nature 2000, 407, 711-7.
18. Obmolova, G.; Ban, C.; Hsieh, P.; Yang, W. Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. Nature 2000, 407, 703-10.
19. Aquilina, G.; Bignami, M. Mismatch repair in correction of replication effors and processing of DNA damage. J. Cell Physiol. 2001, 187, 145-54.
20. Modrich, P.; Lahue, R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu. Rev. Biochem. 1996, 65, 101-33.
21. Jiricny, J.; Nystrom-Lahti, M. Mismatch repair defects in cancer. Curr. Opin. Genet. Dev. 2000, 10, 157-61.
22. Buermeyer, A.B.; Deschenes, S.M.; Baker, S.M.; Liskay, R.M. Mammalian DNA mismatch repair. Ann. Rev. Genet. 1999, 33, 533-564.
23. Bignami, M.; Casorelli, I.; Karran, P. Mismatch repair and response to DNA-damaging antiturnour therapies. Eur. J. Cancer 2003, 39, 2142-9.
24. Fishel, R.; Lescoe, M.K.; Rao, MR.; Copeland, N.F.; Jenkings, N.A.; Garber, J.; Kane, M; Kolodner, R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993, 75, 1027-1038.
25. Fink, D.; Aebi, S.; Howell, S.B. The Role of DNA Mismatch Repair in Drug Resistance. Clin. Cancer Res. 1998, 4, 1-6.
26. Stoijic, L.; Brun, R.; Jiricny, J. Mismatch repair and DNA damage signalling. DNA Repair 2004, 3, 1091-101
27. Fedier, A.; Fink, D. Mutations in DNA mismatch repair genes: implications for DNA damage signalling and drug sensitivity. Int. J. Oncol. 2004, 24, 1039-47.
28. Karran, P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 2001, 22, 1931-7.
29. Hurley, L.H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2002, 2, 188-200.
30. Chaney, S.Q.; Sancar, A. DNA repair: enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst. 1996, 88, 1346-60.
31. Scharer, O.D. Chemistry and biology of DNA repair. Angew. Chem. Int. Ed. Engl. 2003, 42, 2946-74.
32. Middleton, M.R.; Margison, G.P. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol. 2003, 4, 37-44.
33. Duckett, D.R.; Drummond, J.T.; Murchic, A.I.; Reardon, J.T.; Sancar, A.; Lilley, D.M.; Modrich, P. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA 1996, 93, 6443-7.
34. Kat, A.; Thilly, W.G.; Fang, W.H.; Longley, M.J.; Li, G.M.; Modrich, P. An alkylation-tolerant, imitator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. USA 1993, 90, 6424-8.
35. Carethers, J.M.; Hawn, M.T.; Chauhan, D.P.; Luce, M.C.; Marra, G.; Koi, M.; Boland, C.R. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro-N nitrosoguanidine. J. Clin. Invest. 1996, 98, 199-206.
36. Koi, M.; Umar, A.; Chauhan, D.P.; Cherian, S.P.; Carethers, J.M.; Kunkel, T.A.; Boland, C.R.; Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLHI mutation. Cancer Res. 1994, 54, 4308-12.
37. Liu, L.; Markowitz, S.; Gerson, S.L.; Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res. 1996, 56, 5375-9.
38. Tentori, L.; Orlando, L.; Lacal, P.M.; Benincasa, E.; Faraoni, I.; Bonmassar, E.; D'Atri, S.; Graziani, G. Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol. Pharmacol. 1997, 52, 249-58.
39. Taverna, P.; Liu, L.; Hanson, A.J.; Monks, A.; Gerson, S.L. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother. Pharmacol. 2000, 46, 507-16.
40. D'Atri, S.; Tentori, L.; Lacal, P.M.; Graziani, G.; Pagani, E.; Benincasa, E.; Zambruno, G.; Bonmassar, E.; Jiricny, J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol. 1998, 54, 334-41.
41. Drablos, F.; Feyzi, E.; Aas, P.A.; Vaagbo, C.B.; Kavli, B.; Bratlie, M.S.; Pena-Diaz, J.; Otterlei, M.; Slupphaug, G.; Krokan, H.E. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair 2004, 3, 1389-407.
42. Aquilina, G.; Ceccotti, S.; Martinelli, S.; Hampson, R.; Bignami, M. N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Res. 1998, 58, 135-41.
43. Aquilina, G.; Crescenzi, M.; Bignami, M. Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage. Carcinogenesis 1999, 20, 2317-26.
44. Friedman, H.S.; Johnson, S.P.; Dong, Q.; Schold, S.C.; Rasheed, B.K.; Bigner, S.H.; Ali-Osman, F.; Dolan, E.; Colvin, O.M.; Houghton, P.; Germain, G.; Drummond, J.T.; Keir, S.; Marcelli, S.; Bigner, D.D.; Modrich, P. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res. 1997, 57, 2933-6.
45. Margison, G.P.; Povey, A.C.; Kaina, B.; Santibanez; Koref, M.F. Variability and regulation of O6-alkylguanine-DNA alkyltransterase. Carcinogenesis. 2003, 24, 625-35.
46. Bignami, M.; O'Driscoll, M.; Aquilina, G.; Karran, P. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat. Res. 2000, 462, 71-82.
47. Liu, L.; Markowitz, S.; Gerson, S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res. 1996, 56, 5375-9.
48. Pepponi, R.; Marra, G.; Fuggetta, M.P.; Falcinelli, S.; Pagani, E.; Bonmassar, E.; Jiricny, J.; D'Atri, S. The effect of O6-alkylguanine DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2 chloroethyl)1-nitrosourea, and cisplatin. J. Pharmacol. Exp. Ther. 2003, 304, 661-8.
49. Sancar, A. DNA excision repair. Annu. Rev. Biochem. 1996, 65, 43-81.
50. Fink, D.; Nebel, S.; Norris, P.S.; Aebi, S.; Kim, H.K.; Haas, M.; Howell, S.B; The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br. J. Cancer 1998, 77, 703-8.
51. Aebi, S.; Fink, D.; Gordon, R.; Kim, H.K.; Zheng, H.; Fink, J.L; Howell, S.B. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin. Cancer Res. 1997, 3, 1763-7.
52. Osborne, M.R.; Lawley, P.D. Alkylation of DNA by melphalan with special reference to adenine derivatives and adenine-guanine cross-linking. Chem. Biol. Interact. 1993, 89, 49-60.
53. Maccubbin, A.E.; Caballes, L.; Riordan, J.M.; Huang, D.H.; Gurtoo, H.L. A cyclophosphamide/DNA phosphoester adduct formed in vitro and in vivo. Cancer Res. 1991, 51, 886-92.
54. Fiumicino, S.; Martinelli, S.; Colussi, C.; Aquilina, G.; Leonetti, C.; Crescenzi, M.; Bignami, M. Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts. Int. J. Cancer 2000, 85, 590-6.
55. Tomasz, M.; Chowdary, D.; Lipman, R.; Shimotakahara, S.; Veiro, D.; Walker, V.; Verdine, G.L. Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of the major covalent adduct. Proc. Natl. Acad. Sci. USA 1986, 83, 6702-6.
56. De Silva, I.U.; McHugh, P.J.; Clingen, P.H.; Hartley, J.A. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell Biol. 2000, 20, 7980-90.
57. Thacker, J. The role of homologous recombination processes in the repair of severe forms of DNA damage in mammalian cells. Biochimie. 1999, 81, 77-85.
58. Pichierri, P.; Franchitto, A.; Piergentili, R.; Colussi, C.; Palitti, F. Hypersensitivity to camptothecin in MSH2 deficient cells is correlated with a role for MSH2 protein in recombinational repair. Carcinogenesis 2001, 22, 1781-7.
59. de Wind, N.; Dekker, M.; Berns, A.; Radman, M.; te Riele, H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995, 82, 321-30.
60. Chen, W.; Jinks-Robertson, S. The role of the mismatch repair machinery in regulating mitotic and meiotic recombination between diverged sequences in yeast. Genetics 1999, 151, 1299-313.
61. Estlin, E.J. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine. Cancer Treat. Rev. 2001, 27, 351-63.
62. Hawn, M.T.; Umar, A.; Carethers, J.M.; Marra, G.; Kunkel, T.A.; Boland, C.R.; Koi, M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 1995, 55, 3721-5.
63. Swann, P.F.; Waters, T.R.; Moulton, D.C.; Xu, Y.Z.; Zheng, Q.; Edwards, M.; Mace, R. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996, 273, 1109-11.
64. Buermeyer, A.B.; Wilson-Van Patten, C.; Baker, S.M.; Liskay, R.M. The human MLH1 cDNA complements DNA mismatch repair defects in Mlh1-deficient mouse embryonic fibroblasts. Cancer Res. 1999, 59, 538-41.
65. Yan, T.; Berry, S.E.; Desai, A.B.; Kinsella, T.J. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells. Clin. Cancer Res. 2003, 9, 2327-34.
66. Kandel, E.S.; Skeen, J.; Majewski, N.; Di Cristofano, A.; Pandolfi, P.P.; Feliciano, C.S.; Gartel, A.; Hay, N. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol. Cell Biol. 2002, 22, 7831-41.
67. Milas, L.; Fujii, T.; Hunter, N.; Elshaikh, M.; Mason, K.; Plunkett, W.; Ang, K.K.; Hittelman, W. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 1999, 59, 107-14.
68. Robinson, B.W.; Im, M.M.; Ljungman, M.; Praz, F.; Shewach, D.S. Enhanced radiosensitization with gemcitabine in mismatch repair deficient HCT116 cells. Cancer Res. 2003, 63, 6935-41.
69. van Bree, C.; Rodermond, H.M.; de Vos, J.; Haveman, J.; Franken, N.A. Mismatch repair proficiency is not required for radioenhancement by gemcitabine. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62, 1504-9.
70. Fedier, A.; Schwarz, V.A.; Walt, H.; Carpini, R.D.; Haller, U.; Fink, D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int. J. Cancer 2001, 93, 571-6.
71. Takahashi, T.; Min, Z.; Uchida, I.; Arita, M.; Watanabe, Y.; Koi, M.; Hemmi, H. Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors. Cancer Lett. 2005, 220, 85-93.
72. Mader, R.M.; Muller, M.; Steger, G.G. Resistance to 5-fluorouracil. Gen. Pharmacol. 1998, 31, 661-6.
73. Carethers, J.M.; Chauhan, D.P.; Fink, D.; Nebel, S.; Bresalier, R.S.; Howell, S.B.; Boland, C.R. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999, 117, 123-31.
74. Meyers, M.; Wagner, M.W.; Hwang, H.S.; Kinsella, T.J.; Boothman, D.A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 2001, 61, 5193-201.
75. Meyers, M.; Hwang, A.; Wagner, M.W.; Boothman, D.A. Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ. Mol. Mulagen. 2004, 44, 249-64.
76. Tajima, A.; Hess, M.T.; Cabrera, B.L.; Kolodner, R.D.; Carethers, J.M. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004, 127, 1678-84.
77. Goel, S.; Bulgaru, A.; Hochster, H.; Wadler, S.; Zamboni, W.; Egorin, M.; Ivy, P.; Leibes, L.; Muggia, F.; Lockwood, G.; Harvey, E.; Renshaw, G.; Mani, S. Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors. Ann. Oncol. 2003, 14, 1682-7.
78. Ribic, C.M.; Sargent, D.J.; Moore, M.J.; Thibodeau, S.N.; French, A.J; Goldberg, R.M.; Hamilton, S.R.; Laurent-Puig, P.; Gryfe, R.; Shepherd, L.E.; Tu, D.; Redston, M.; Gallinger, S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003, 349, 247-57.
79. Boulikas, T.; Vougiouka, M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol. Rep. 2004, 11, 559-95.
80. Drummond, J.T.; Anthoney, A.; Brown, R.; Modrich, P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem. 1996, 271, 19645-8.
81. Aebi, S.; Kurdi-Haidar, B.; Gordon, R.; Cenni, B.; Zheng, H.; Fink, D.; Christen, R.D.; Boland, C.R.; Koi, M.; Fishel, R.; Howell, S.B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996, 56, 3087-90.
82. Fink, D.; Nebel, S; Aebi, S.; Zheng, H.; Kim, H.K.; Christen, R.D; Howell, S.B. Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues. Br. J. Cancer 1997, 76, 890-3.
83. Fink, D.; Nebel, S.; Aebi, S.; Zheng, H.; Cenni, B.; Nehme, A.; Christen, R.D.; Howell, S.B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996, 56, 4881-6.
84. Papouli, E.; Cejka, P.; Jiricny, J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res. 2004, 64, 3391-4.
85. Kartalou, M.; Essigmann, J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478,23-43.
86. Lin, X.; Ramamurthi, K.; Mishima, M.; Kondo, A.; Christen, R.D.; Howell, S.B. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res. 2001, 61, 1508-16.
87. Lin, X.; Kim, H.K.; Howell, S.B. The role of DNA mismatch repair in cisplatin mutagenicity. J. Inorg. Biochem. 1999, 77, 89-93.
88. Wang, J.C. DNA Topoisomerases. Ann. Rev. Biochem. 1996, 65, 635-692.
89. D'Arpa, P.; Liu, L.F. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta. 1989, 989, 163-77.
90. Holden, J.A. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic. Curr. Med Chem. Anti-Canc. Agents 2001, 1, 1-25.
91. Li, T.K.; Liu, L.F. Tumor cell death induced by topoisomerase targeting drugs. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 53-77.
92. Jacob, S.; Aguado, M.; Fallik, D.; Praz, F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res. 2001, 61, 6555-62.
93. Hsiang, Y.H.; Liu, L.F.; Wall, M.E.; Wani, M.C.; Nicholas, A.W.; Manikumar, G.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 1989, 49, 4385-9.
94. Ryan, A.J.; Squires, S.; Strutt, H.L.; Johnson, R.T. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res. 1991, 19, 3295-300.
95. Arnaudeau, C.; Rozier, L.; Cazaux, C.; Defais, M.; Jenssen, D.; Helleday, T. RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors. Nucleic Acids Res. 2001, 29, 662-7.
96. Pommier, Y.; Redon, C.; Rao, V.A.; Seiler, J.A.; Sordet, O.; Takemura, H.; Antony, S.; Meng, L.; Liao, Z.; Kohlhagen, G.; Zhang, H.; Kohn, K.W. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat. Res. 2003, 532, 173-203.
97. Alani, E.; Reenan, R.A.; Kolodner, R.D. Interaction between mismatch repair and genetic recombination in Saccharomyces cerevisiae. Genetics 1994, 137, 19-39.
98. Evans, E.; Sugawara, N.; Haber, J.E.; Alani, E. The Saccharomyces cerevisiae Msh2 mismatch repair protein localizes to recombination intermediates in vivo. Mol. Cell. 2000, 5, 789-99.
99. Chen, W.; Jinks-Robertson, S. Mismatch repair proteins regulate heteroduplex formation during mitotic recombination in yeast. Mol. Cell Biol. 1998, 18, 6525-37.
100. Jacob, S.; Miquel, C.; Sarasin, A.; Praz, F. Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines. Nucleic Acids Res. 2005, 33, 106-13.
101. Fox, M.E.; Smith, P.J. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res. 1990, 50, 5813-8.
102. Liu, W.M.; Te Poele, R.H.; Joel, S.P. Re: Loss of the DNA Mismatch Repair: Effects on the Rate of Mutation to Drug Resistance. J. Natl. Cancer Inst. 1998, 90, 246.
103. Gatto, B.; Leo, E. Drugs acting on the beta isoform of human topoisomerase II (p180). Curr. Med Chem. Anti-Canc. Agents 2003, 3, 173-85.
104. Boger, D.L.; Johnson, D.S. CC-1065 and the Duocarmycins: Understanding their Biological Function through Mechanistic Studies. Angew. Chem. Int. Ed. Engl. 1996, 35, 1438-74.
105. Fedier, A.; Fowst, C.; Tursi, J.; Geroni, C.; Haller, U.; Marchini, S.; Fink, D. Brostallicin (PNU-166196)- a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. Br. J. Cancer 2003, 89, 1559-65.
106. Colella, G.; Marchini, S.; D'Incalci M.; Brown, R.; Broggini, M. Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br. J. Cancer 1999, 80, 338-43.
107. Lockhart, A.C.; Howard, M.; Hande, K.R.; Roth, B.J.; Berlin, J.D.; Vreeland, F.; Campbell, A.; Fontana, E.; Fiorentini, F.; Fowst, C.; Paty, V.A.; Lankford, O.; Rothenberg, M.L. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin. Cancer Res. 2004, 10, 468-75.
108. Ten Tije, A.J.; Verweij, J.; Sparreboom, A.; Van Der Gaast, A.; Fowst, C.; Fiorentini, F.; Tursi, J.; Antonellini, A.; Mantel, M.; Hartman, C.M.; Stoter, G.; Planting, A.S.; De Jonge, M.J. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin. Cancer Res. 2003, 9, 2957-64.
109. Cozzi, P.; Beria, I.; Caldarelli, M.; Capolongo, L.; Geroni, C.; Mongelli, N. Cytotoxic halogenoacrylic derivatives of distamycin A. Bioorg. Med. Chem. Lett. 2000, 10, 1269-72.
110. Geroni, C.; Marchini, S.; Cozzi, P.; Galliera, E.; Ragg, E.; Colombo, T.; Battaglia, R.; Howard, M.; D'Incalci, M.; Broggini, M. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res. 2002, 62, 2332-6.
111. Cozzi, P. The discovery of a new potential anticancer drug: a case history. Farmaco 2003, 58, 213-20.
112. Hadfield, J.A.; Ducki, S.; Hirst, N.; McGown, A.T. Tubulin and microtubules as targets for anticancer drugs. Prog. Cell Cycle Res. 2003, 5, 309-25.
113. Picard, S.F.; Franco, N.; Sergent, C.; Chauffert, B.; Lizard-Nacol, S. Analysis of microsatellite instability in acquired drug-resistance human tumor cell lines. Oncol. Rep. 2002, 9, 971-6.
114. Moreland, N.J.; Illand, M.; Kim, Y.T.; Paul, J.; Brown, R. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res. 1999, 59, 2102-6.
115. Esteller, M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 629-56.
116. Brueckner, B.; Lyko, F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci. 2004, 25, 551-4.
117. Plumb, J.A.; Strathdee, G.; Sludden, J.; Kaye, S.B.; Brown, R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000, 60, 6039-44.
118. Arnold, C.N.; Goel, A.; Boland, C.R. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int. J. Cancer 2003, 106, 66-73.
119. Curtin, N.J.; Wang, L.Z.; Yiakouvaki, A.; Kyle, S.; Arris, C.A.; Canan-Koch, S.; Webber, S.E.; Durkacz, B.W.; Calvert, H.A.; Hostomsky, Z.; Newell, D.R. Novel poly(ADP-ribose) polymerasc-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res. 2004, 10, 881-9.
120. Brown, R.; Hirst, G.L.; Gallagher, W.M.; McIlwrath, A.J.; Margison, G.P.; van der Zee, A.G.; Anthoncy, D.A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997, 15, 45-52.
121. Pots, K.; Paniwnyk, Z.; Ruparelia, K.C.; Teesdale-Spittle, P.H.; Hartley, J.A.; Kelland, L.R.; Patterson, L.H. Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells. J. Med. Chem. 2004, 47, 1856-9.
122. Pots, K.; Paniwnyk, Z.; Teesdale-Spittle, P.; Plumb, J.A.; Willmore, E.; Austin, C.A.; Patterson, L.H. Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer. Mol. Cancer Ther. 2003, 2, 607-10.
123. Fan, J.Y.; Ohms, S.J.; Boyd, M.; Denny, W.A. DNA adducts of 9-anilinoacridine mustards: characterization by NMR. Chem. Res. Toxicol. 1999, 12, 1166-72.
124. Kohn, K.W.; Orr, A.; O'Connor, P.M.; Guziec, L.J.; Guziec, F.S. Jr. Synthesis and DNA-sequence selectivity of a series of mono- and difunctional 9-aminoacridine nitrogen mustards. J. Med. Chem. 1994, 37, 67-72.
125. Chen, W.D.; Eshleman, JR.; Aminoshariae, M.R.; Ma, A.H.; Veloso, N.; Markowitz, S.D.; Sedwick, W.D.; Veigl, M.L. Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells. J. Natl. Cancer Inst. 2000, 92, 480-5.
126. Pots, K.; Plumb, J.A.; Brown, R.; Teesdale-Spittle, P.; Searcey, M.; Smith, P.J.; Patterson, L.H. Development of non-symmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells. J. Med. Chem. 2005, in press.
127. Anthoney, D.A.; McIlwrath, A.J.; Gallagher, W.M.; Edlin, A.R.; Brown, R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res. 1996, 56, 1374-81.
128. Jansen, B.A.; Brouwer, J.; Reedijk, J. Glutathione Induces Cellular Resistance against Cationic Dinuclear Platinum Anticancer Drugs. J. Inorg. Biochem. 2002, 89, 197-202.
129. Parker, R.J.; Eastman, A.; Bostick-Bruton, F.; Reed, E. Acquired 17 Resistance in Human Ovarian Cancer Cells is Associated with Enhanced Repair of 17-DNA Lesions and Reduced Drug Accumulation. J. Clin. Invest. 1991, 87, 772-777.
130. Kelland, L.R.; Barnard, C.F.; Mellish, K.J.; Jones, M.; Goddard, P.M.; Valenti, M.; Bryant, A.; Murrer, B.A.; Harrap, K.R. A Novel Trans-Platinum Coordination Complex Possessing in vitro and in vivo Antitumour Activity. Cancer Res. 1994, 54, 5618-22.
131. Strathdee, G.; MacKeen, M. J.; Illand, M. and Brown, R. A Role for Methylation of the hMLH1 Promoter in Loss of hMLH1 Expression and Drug Resistance in Ovarian Cancer, Oncogene 1999, 18, 2335-2341.
132. Brown, R.; Hirst, G.L.; Gallagher, W.M.; McIlwrath, A.J.; Margison, G.P.; van der Zee, A.G.; Anthoney, D.A. hMLH1 Expression and Cellular Responses of Ovarian Tumour Cells to Treatment with Cytotoxic Anticancer Agents. Oncogene 1997, 15, 45-52.
133. Lage, H.; Dietel, M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol. 1999, 125, 156-65.
134. Issa, J.P.; Garcia-Manero, G.; Giles, F.J.; Mannari, R.; Thomas, D.; Faderl, S.; Bayar, E.; Lyons, J.; Rosenfeld, C.S.; Cortes, J.; Kantarjian, H.M. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoictic malignancies. Blood 2004, 103, 1635-40.
135. Sabbatini, P.; Spriggs, D. Salvage therapy for ovarian cancer. Oncology 1998, 12, 833-43.
136. Piccart, M.J.; Lamb, H.; Vermorken, J.B. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann. Oncol. 2001, 12, 1195-203.